Forte Research Systems and Virtify Partner for Simplified Compliance with Disclosure Regulations


Company News Release

Forte Research Systems, Inc.

, a developer of clinical trial management systems (


), and

Virtify, Inc.

, a provider of structured content management software solutions for life sciences, announced today a partnership that aims to simplify compliance with disclosure requirements of the Food and Drug Administration Amendments Act (FDAAA). The agreement addresses the increasingly stringent regulations imposed on clinical research institutions.

The integration will take place between Forte's OnCore® system, an enterprise-class

clinical research management system

utilized by academic medical centers and cancer centers, and the

Virtify CTRR

(Clinical Trial Registration & Results) software, which streamlines and automates the mandatory disclosure postings to the online registry and results database.

"Collaborating with Virtify allows us to provide a seamless and sophisticated experience for OnCore users as they comply with these regulations," said Srini Kalluri, Founder, CEO, and Chief Customer Officer at Forte. "OnCore is a proven system that supports streamlined management of robust portfolios of clinical trials. Coupled with the many benefits of the Virtify CTRR, OnCore becomes the most comprehensive solution available for compliance with clinical trial disclosure requirements."

Among the benefits offered by Virtify CTRR is an easy-to-use centralized compliance monitoring system for clinical trials. It offers the status of all trial disclosures and helps users proactively identify their risks related to trial disclosure and non-compliances.

When integrated with the OnCore system, the Virtify solution will provide an end-to-end disclosure solution. "It will extend CTRR's robust disclosure process management features to the OnCore system, which in turn will be able to share data directly with Virtify CTRR," said Satish Tadikonda, CEO of Virtify. "The ability of the systems to communicate means that duplicate data entry will be eliminated."

The new agreement is the most recent among several collaborations in which Forte has joined with industry leaders to provide comprehensive solutions and eliminate data silos. "With Virtify's extensive experience and expertise in the clinical trial disclosure arena, it makes perfect sense to partner with them rather than reinventing the wheel," Kalluri said. "This will continue to be our strategy in order to bring greater efficiencies to the industry."

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.